Improving Engagement From Underserved Communities With Prostate Cancer Genetics Services

NCT07407686 | Not Yet Recruiting

• 1 other identifier: 361063
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

Earlier work explored barriers and facilitators to accessing prostate cancer screening, particularly in underserved communities, and provided valuable insights to build upon. This study will explore perspectives on how genetic risk for prostate cancer is explained and understood through in-depth interviews with members of underserved communities. Findings from this work, alongside earlier results, will be used to co-design clear and accessible digital educational resources in collaboration with community members and relevant charities. Participation in cancer screening programmes in the UK varies, with differences linked to socioeconomic status, ethnicity and health literacy. Similar inequalities are seen in access to prostate cancer genetics services, indicating a need for improved engagement. Successful integration of genetics into prostate cancer care requires clear and inclusive information about genetic testing processes, possible outcomes and interpretation of results. Currently, there are limited resources explaining genetic risk for prostate cancer in an accessible way. Co-production with representatives from underserved communities will ensure that educational materials are understandable, relevant and acceptable to all.

Conditions

Prostate Cancer

Keywords

qualitative research methods; co-production; MRC Complex Intervention Developement; Health Literacy and Health Behaviour Theories; Prostate cancer screening in high risk groups; semi-structured interviews and focus groups; reflexive thematic analysis of qualitative data; Evaluation of outputs

Outcome Measures

Primary Outcomes (3)

• Evaluation of educational materials, demonstrating that users have an increase in understanding or prostate cancer risk and symptoms as well as genetic risk.

  Using surveys (before and after use of resources) and interviews to measure improvement in understanding in individuals without experience of prostate cancer.

  February 2026 to August 2026

• Increased representation from underserved groups in the referrals to our genetic research studies.

  Using demographic data from referrals via our website to our genetic research studies

  As soon as the educational materials are live, which we aim to be from June 2026, increase in referrals to our genetic research studies from under-represented groups will be measured. This will take place for 12 months.

• Qualitative data such as hits to the webpage and scroll depth and how many have signed up to the genetic research studies via the website.

  This is a short term measure of how effective and engaging the resources are.

  These data will be collected from as soon as the webpage goes live for the subsequent 12 months.

Secondary Outcomes (2)

• Improved representation of underrepresented groups in our genetic risk studies.

  Measurements of the demographics of our research participants takes place currently. Any signficant change in representation will be reported for a minimum 12 months after the webpage and resources go live.

• Reduced barriers to prostate cancer screening and participation in genetic research faced by underrepresented communities

  The web page will go live in July 2026 and will be a long term resource (many years), regularly updated by our team. There will also be rounds of evaluation, using surveys and interviews, with subsequent adaption.

Study Arms (1)

Semi-structured interview participants

Up to 60 participants for semi-structured interviews, 20 from each of the following underserved groups in prostate cancer screening; Black African and Black Caribbean, transgender and non-binary with a prostate, reduced access to healthcare.

Other: Surveys; Other: Semi-structured interviews and focus groups

Interventions

Surveys OTHER

Up to 30 surveys with 10 of these individuals undergoing short interviews to assess the improvement of their understanding around prostate cancer

Semi-structured interview participants

Semi-structured interviews and focus groups OTHER

Up to 60 total semi-structured interviews (up to 20 per underserved group) to assess barriers and facilitators to prostate cancer screening and how they would like information to improve their understanding to be presented.

Semi-structured interview participants

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Men and people with prostates from the following three communities: * Black African and Black Caribbean * Transgender women and non-binary people with prostates * Reduced access to healthcare

You may qualify if:

• Men and people with prostates age 18 and above
• Those who belong to the three underserved groups; Black African and Black Caribbean Ancestry, transgender and non-binary people with a prostate and those with reduced access to healthcare
• We allow intersectionality within reason and will narratively describe any instances of these in the writeup of findings
• Individuals with and without a lived experience of prostate cancer

You may not qualify if:

• To avoid exhaustion, we will only allow participation in two interview or focus groups per individual for the entirety of the study
• Those without capacity to consent to interview (capacity is assumed unless there is good reason to believe otherwise)

Sponsors & Collaborators

• Royal Marsden NHS Foundation Trust: lead

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Surveys and Questionnaires; Focus Groups

Condition Hierarchy (Ancestors)

Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Genital Diseases, Male; Genital Diseases; Urogenital Diseases; Prostatic Diseases; Male Urogenital Diseases

Intervention Hierarchy (Ancestors)

Data Collection; Epidemiologic Methods; Investigative Techniques; Health Care Evaluation Mechanisms; Quality of Health Care; Health Care Quality, Access, and Evaluation; Public Health; Environment and Public Health

Study Officials

• Ros Eeles

  Institute of Cancer Research, United Kingdom

  STUDY CHAIR

Central Study Contacts

Rose Hall, MMBS

CONTACT

0000000000000000; rose.hall@icr.ac.uk

Elizabeth Bancroft

CONTACT

prostate.research@rmh.nhs.uk

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 21, 2025
• First Posted: February 12, 2026
• Study Start: February 28, 2026
• Primary Completion (Estimated): December 31, 2027
• Study Completion (Estimated): December 31, 2027
• Last Updated: February 12, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share